@article{1db44414e1ee44b4aeec14de8e9cdccd,
title = "The phosphate bucket list",
abstract = "As our understanding of phosphate homeostasis has expanded over the last 20 years, additional quandaries have surfaced. Though the phosphate bucket list remains full, we are confident that the next 20 years will lead to major fundamental discoveries. In this commentary, we provide an example of how findings from a basic study that examined the mechanisms for circadian rhythms of plasma and urinary phosphate sheds light on important pathways that can be harnessed for novel therapeutic approaches in the future.",
author = "Tamara Isakova and Geoffrey Block",
note = "Funding Information: TI is supported by grants R01DK110087, R01DK102438, and U01DK099930 from the National Institutes of Health. GB is supported by grants U01DK097093 and R01DK102438 from the National Institutes of Health. Funding Information: TI received grant support from Shire and an honorarium from Bayer. GB has served as a consultant for Akebia, Amgen, Ardelyx, AstraZeneca, Celgene, Daiichi Sankyo, Keryx, Relypsa, Sanfit, and ZS Pharma; has ownership interest in Ardelyx and Nephroceuticals; and has received research support from Keryx and honoraria from Akebia, Amgen, AstraZeneca, Celgene, Daiichi Sankyo, Keryx, and Sanofi. Publisher Copyright: {\textcopyright} 2018 International Society of Nephrology",
year = "2018",
month = may,
doi = "10.1016/j.kint.2018.01.010",
language = "English (US)",
volume = "93",
pages = "1033--1035",
journal = "Kidney international",
issn = "0085-2538",
publisher = "Elsevier B.V.",
number = "5",
}